At any point in time, the InCube team is working on several innovations that have the potential to positively impact the lives of millions of patients and disrupt their respective markets. Some are research projects and others are companies on the path to commercialization. Learn more about our work by clicking on the company logos below.
Oral Biologics Delivery vs. Making Oral Biologics a Reality
The concept for Rani was developed by Mir Imran, a prolific medical inventor and entrepreneur who has founded more than twenty life sciences companies.
Rani was established as a company in 2012 after several years as a research project within InCube Labs, Mir’s multi-disciplinary life sciences lab focused on developing and commercializing breakthrough innovations.
The Rani platform is capable of delivering a wide range of biologics for the treatment of various chronic diseases.
View Company
Treatment of overactive bladder with sacral nerve stimulation
SacraMed is a medical technology company focused on the development of a neuromodulation system for the treatment of Overactive bladder (OAB). OAB is a bladder disorder that results in an abnormal urge to urinate, with or without urinary incontinence.
It can occur at any age, but is most common in the elderly population. Approximately 1 in 6 adults suffers from OAB. It is a treatable condition, and at SacraMed we are working on advancing the tools and techniques to help bring relief to patients.
Breakthrough Therapy for Iron Deficiency Anemia
Fe3 is an early stage company developing a novel transdermal therapy for the treatment of iron deficiency anemia. The approach and technology for Fe3 was developed at InCube Labs, a multi-disciplinary life sciences R&D lab focused on developing breakthrough medical innovations.
25 million people in the US alone have mild to moderate anemia, making it one of the most prevalent micro-nutrient deficiencies.
Medical Therapy to
Treat Epilepsy
Neurolink is an early stage company developing a novel therapy for the treatment of epilepsy.
Nearly three million Americans suffer from epilepsy, a neurological condition characterized by seizures. One of the most common neurological diseases, epilepsy affects approximately 1% of the population - 1 in 26 people will have epilepsy in their lifetime.
Implantable drug-device combination therapy for brain cancer
Theracle is developing an implantable drug-device combination therapy for gliomas.
The approach uses an implantable drug-delivery device, bypassing the blood-brain barrier. The device will provide an ability to focus treatment directly at the cancer site using one or more drugs, and it is expected that treatment will result in no peripheral adverse effects. It is planned to pursue an FDA orphan drug designation, with fast-track status towards regulatory approval.
View Company
New Therapy for
Atrial Fibrillation
Corhythm is an early stage company developing a novel therapy for the treatment of atrial fibrillation.
The approach and technology for Corhythm was developed at InCube Labs, a multi-disciplinary life sciences R&D lab focused on developing breakthrough medical innovations.
Developing novel treatments for gastrointestinal disorders
Python has developed innovations for resolving post-surgical leaks, bioresorbable devices to promote rapid healing, and prosthetic implants to restore GI function.
Designed to help the more than 600,000 patients who have colon resections, among other GI surgeries.
Remote monitoring of patients
iBridge is developing a remote patient monitoring system to wirelessly manage patients with active implants.
Our technology platform can be used for enhanced disease management of patients with active implanted medical devices for improved patient care.
Gastric stimulation for the treatment of obesity
IntraPace is developing an innovative product platform utilizing gastric stimulation for the treatment of obesity.
IntraPace was founded in 2001 to address an unmet need in weight loss surgery by developing a gentler solution for weight loss that incorporates essential components of behavior therapy. The abiliti system is intended to enable patients to achieve and sustain significant weight loss without the complications, lifestyle restrictions and substantial anatomical changes associated with the established weight loss surgeries.
...
Developing novel treatments for gastrointestinal disorders
Entrack is developing novel treatments for gastrointestinal disorders including Crohn's disease and ulcerative colitis.
We have developed innovations for IBD diagnosis as well as inflammation and ischemia sensing, sensor based closed loop localized drug delivery, and surgical marking.
Innovative implantable devices for the management of chronic pain
The company pioneered the developed of an implantable stimulator for the treatment of chronic pain. More than 5M people in the US suffer from chronic pain. The Spinal implant stimulates the Dorsal Root Ganglia, and showed significant improvement in clinical efficacy over traditional spinal cord stimulation. The company was acquired by St. Jude Medical.
Therapy for Neurovascular Aneurysms
NFocus developed the innovative LUNA™ product, a single-deployment, easy-to-use embolization device designed to be a direct replacement to detachable coils for the treatment of brain aneurysms and hemorrhagic stroke.
The company was acquired by Covidien, which was then acquired by Medtronic.
Compact ultrasound systems
Zonare developed, manufactured and commercialized compact ultrasound systems that are used for diagnostic imaging in a range of clinical applications and settings.
Its product platform, the z.one ultrasound system, was based on its unique data acquisition and image formation technology, Zone Sonography. The company was acquired by Mindray.
Endocardial mapping and ablation technologies
Cardiac Pathways pioneered endocardial mapping and ablation technologies for the treatment of ventricular and atrial arrhythmias. The company’s minimally-invasive systems were used by electrophysiologists to diagnose and treat cardiac tachyarrhythmia (abnormally rapid heart rhythms), which if untreated can cause palpitations, fainting, and sudden cardiac arrest.
The company was acquired by Boston Scientific.
Transurethral needle ablation
Vidamed developed a non-surgical therapy designed to deliver low-level, precisely controlled radiofrequency energy directly to the prostrate to diminish obstructing tissue associate with Benign Prostatic Hyperplasia (BPH).
The company was acquired by Medtronic.
Interventional cardiology
Percusurge pioneered the concept of embolic protection during interventional procedures, revolutionizing the field of interventional cardiology by recognizing and solving the problem of distal embolization.
Its initial product, the Guardwire™, was designed to capture material dislodged within arteries, and to prevent clots/debris from traveling distally. The company was acquired by Medtronic.
Compact advanced imaging system
SafeView has developed next-generation imaging technology for Homeland Security applications, with a mm wave radar technology that can be tuned to detect any objects under clothing.
This technology is being adopted by airports worldwide in configurations that generate 3-D holographic images of travelers, which reveal images of objects that may be hidden in clothing and boots. Safeview was acquired by L-3 Communications in 2006.
Neuro-diagnostic devices
Physiometrix developed neuro-diagnostic devices including depth of anesthesia devices.
The PSArray Electrode Sensor product measured the effects of a patient's response to anesthetic agents.
The device provides feedback to anesthesiologists to more precisely maintain appropriate anesthesia levels, while minimizing the risk of under or over medicating. As a result, the patient’s recovery is faster, including speedier discharge from the hospital. The company went public in 1996 and was subsequently acquired by Hospira.
View CompanyRani Therapeutics has developed a solution for the oral delivery of biologic drugs, what many consider the “Holy Grail of Drug Delivery.” The company has an extensive patent portfolio and has demonstrated equivalence with subcutaneous injections in preclinical studies.
The company is currently preparing for human studies to test the RaniPill™ device with its first drug, Octreotide.
See More